This is a Phase 1, multicenter, open label, single dose study. A total of 30 subjects are planned (5 groups of 6 subjects each) as follows:~Group A: Subjects with ESRD who are receiving hemodialysis treatment~Group B: Subjects with severe renal impairment~Group C: Subjects with moderate renal impairment~Group D: Subjects with mild renal impairment~Group E: Healthy subjects
This is a Phase 1, multicenter, open label, single dose study. A total of 30 subjects are planned (5 groups of 6 subjects each.)